Ewing-based Antares Pharma Inc. on Tuesday announced that Paul K. Wotton has resigned as president and CEO.
Wotton informed the company’s board of directors that he will be the new CEO of a development stage biotechnology company. He also resigned from Antares’ board of directors.
In turn, Antares announced that Eamonn P. Hobbs will serve as its new president and CEO, effective immediately.
“Antares has developed a robust business platform with tremendous potential, and I look forward to leading a strong management team and a group of dedicated and talented employees,” Hobbs said in a statement. “I’ve worked closely with the company over the past five years and believe that our state of the art technologies, product development capabilities and sound regulatory strategy have the potential to produce numerous product approvals over the coming years further enhancing shareholder value.”
According to the announcement, Hobbs joined Antares’ board of directors in 2009 and has more than 30 years of experience in the pharmaceutical, medical device and combination products industry.
Prior to Antares, he was the president and CEO of Delcath Systems Inc., a specialty pharmaceutical and medical device company focused in cancer treatment. Prior to Delcath, he was the president and CEO of AngioDynamics Inc. He also served as executive vice president at E-Z-EM; director of marketing and product development at NAMIC; founder, president and CEO of Hobbs Medical Inc.; and a product development engineer at Cook Incorporated.
“The board is excited about having Mr. Hobbs lead Antares during the next phase of its growth. We have worked closely with Eamonn over the past five years as board members and share his vision for the future,” Leonard S. Jacob, chairman of the board, said in a statement. “The board of Antares wishes Paul success in his new endeavor. I have enjoyed working closely with him over the past five years in building Antares into a fully integrated specialty pharmaceutical company.”
ALSO ON NJBIZ: